Real-world research has released the world's first cancer electric field treatment to benefit Chinese patients.

On September 12, 2020, at the 4th Annual Meeting and 4th China Cerebral Glioma Academic Conference of the Professional Committee of the Chinese Physicians Association, a forward-looking, one-arm observational study was published to evaluate the treatment of tumor electric field Epune in patients with glioblastoma (GBM) in China.
the study published for the first time the efficacy data of tumor electric field therapy in the real world in Chinese groups, further verifying the effectiveness and safety of tumor electric field therapy. The results of the interim analysis of
study showed that the medium non-progression survival was 6.4 months, the medium total survival period had not yet been reached, the secondary non-progression survival period reached 4.5 months, the medium total survival period was 8.6 months, and the most common adverse reactions were mild to moderate skin irritation, all of which were grade I-II.
"As the first real-world study of tumor electric field therapy in group Chinese, the safety and effectiveness of tumor electric field therapy in Chinese patients has been validated in stages," said Professor Jiang Tao of Tiantan Hospital in Beijing, associate director of the Beijing Institute of Neurosurgery and founder of the China Cerebral Glioma Genome Map Database.
with traditional therapies, side effects are concentrated in mild controlled adverse skin reactions.
, this real-world study can be said to be for the clinical treatment of glioblastoma in China injected a strong heart agent.
we will continue to follow up and look further at the long-term data.
real-world study, co-sponsored by Chinese mainland and Hong Kong, China, is the first study of cancer electric field therapy in a Chinese group.
the study included 44 Chinese mainland patients at the Anjian Cancer Treatment Center in Hong Kong, including 29 new GBM patients and 15 relapsed GBM patients.
In order to fully implement General Secretary Xi Jinping's "four most stringent" requirements on drug safety, in April 2019 the State Drug Administration issued the China Drug Regulatory Science Action Plan, which lists "methodology research on the use of real-world data for clinical evaluation of medical devices" as one of the first research projects to help China's drug and medical device research and development and regulatory decision-making.
Professor Zhang Wei, Director of Neurosurgery, Tiantan Hospital, Beijing, said: "In order to provide patients with safer and more effective innovative treatment options, objectively evaluate the use of treatment options in the actual clinical situation, support national regulatory decisions in the field of medical devices, since last year's listing of cancer electric field treatment in Hong Kong, we immediately began to carry out research in the real world with the Hong Kong Anjian Cancer Treatment Center on cancer electric field treatment."
The study, which began last June, is the first to date based on the treatment of tumor electric field in Chinese patients, filling the data gap in the treatment of tumor electric field in patients with glioblastoma in China and providing clinicians with more evidence-based evidence in choosing innovative treatment options.
" glioblastoma (GBM) as the most common and invasive adult brain tumor, patient recurrence rate of up to 100%, five-year survival rate of less than 5%, is considered to be one of the most difficult neurosurgery treatment of difficult tumors.
August 2019, Epdon was awarded the "Innovative Medical Device Qualification", becoming the first innovative therapy approved in Chinese mainland for glioblastoma in 15 years.
"In response to the implementation of real-world research on medical devices by the state, Reding Pharmaceuticals has jointly promoted research in Chinese groups of cancer electric field therapy," said Liang Yi, Chief Commercial Officer and President of Greater China.
very pleased to see that, as a new treatment, the effectiveness and safety of tumor electric field therapy in Chinese groups has been phased out.
the future, we will continue to work closely with the community to further enhance the effectiveness and accessability of cancer electric field treatment for the well-being of patients.
39 Health.com Source: 39 Health.com Copyright Notice: All text, images and audio and video materials that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here.